Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended December 31, 2023, on Wednesday, February 7, 2024.
Related news for (AVXL)
- 24/7 Market News Snapshot 09 September, 2025 – Anavex Life Sciences (NASDAQ:AVXL)
- Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
- MoBot’s Stock Market Highlights – 07/23/25 02:00 PM
- Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
- Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update